DCM
JSPR icon

Driehaus Capital Management’s Jasper Therapeutics JSPR Stock Holding History

Driehaus Capital Management’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-400,000
Closed -$7.24M – 434
2023
Q1 		$7.24M Buy
+400,000
New +$7.39M 0.1% 262

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Driehaus Capital Management's JSPR Position: Q2 2023 in Review

Driehaus Capital Management sold out of Jasper Therapeutics (JSPR) in Q2 2023, closing a stake of 400,000 shares — an estimated $7.24M sold.

Driehaus Capital Management first reported a position in JSPR in Q1 2023 and held it in 1 quarter. The position peaked at $7.24M in Q1 2023. 46 funds tracked by Wall St. Rank hold JSPR as of Q2 2023.

  • Driehaus Capital Management reported no remaining Jasper Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Driehaus Capital Management sold 400,000 Jasper Therapeutics shares in Q2 2023, an estimated $7.24M.
  • Driehaus Capital Management first reported a position in Jasper Therapeutics in Q1 2023 and held it in 1 quarter.
  • Driehaus Capital Management's Jasper Therapeutics position peaked at $7.24M in Q1 2023.
  • 46 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2023.

Based on Driehaus Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.